Why is Novartis stock sliding today?

Shares of Novartis AG dropped 3.5% today after the company announced that its Phase III Lp(a)HORIZON trial for pelacarsen—a next-generation cardiovascular therapy developed jointly with Ionis Pharmaceuticals—did not meet its primary endpoint of reducing major adverse cardiovascular events, including deaths, heart attacks and strokes, compared with placebo.

While the therapy did succeed in lowering lipoprotein(a) concentrations in the blood, that biological effect did not carry over into a substantive reduction in clinical outcomes, thereby eroding the fundamental investment thesis underpinning the asset.

The current selloff extends a negative trend that began to form on September 4, when Novartis shares slipped in the prior regular session and its U.S.-listed depositary shares fell sharply in after-hours trading as early signals of the trial outcome began to surface.

This morning's official top-line data release, published before the Swiss market open, confirmed the failure and intensified the market's reaction.

On the macroeconomic front, the Swiss Market Index fell roughly 1.2% on the day, with Novartis—one of the index's largest components—acting as the primary drag. Across Europe, the pan-regional STOXX 600 slipped 0.1%, pressured by higher oil prices after tit-for-tat U.S.-Iran attacks on vessels in the Strait of Hormuz lifted Brent crude.

Markets are also bracing for an anticipated European Central Bank rate increase later this week, reinforcing a cautious tone across rate-sensitive sectors. With U.S. exchanges closed for the Labor Day holiday, overall liquidity was thinner, amplifying price movements in European trading.

The combination of a high-profile clinical trial failure, a negative pre-session overhang from after-hours ADR trading, and a challenging macro backdrop—rising energy prices, geopolitical tension, and central-bank tightening expectations—converged to push Novartis shares to CHF 125.02, near the session low of CHF 124.60, and well below the stock's 52-week high of CHF 132.68 reached just days earlier.

This article was produced with the assistance of artificial intelligence and reviewed by an editor. For more information, please see our Terms & Conditions.